Welcome to our dedicated page for CHEMED SEC filings (Ticker: CHE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CHEMED's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CHEMED's regulatory disclosures and financial reporting.
CHEMED CORP (CHE) is identified as issuer in a proposed sale for Kevin J. McNamara, identified as an officer: 2,000 common shares, with an aggregate market value of $998,000 and an approximate sale date of September 18, 2026. Raymond James & Associates, Inc. is listed as broker. Two prior sales are listed under the name Kevin K. McNamara: 2,000 shares on August 21, 2026, for $1,082,324 in gross proceeds, and 2,000 shares on August 3, 2026, for $1,079,023 in gross proceeds.
CHEMED CORP (CHE) reported that president and CEO Kevin J. McNamara sold 2,000 shares of Capital Stock on September 18, 2026 in an open-market or private transaction at a weighted average price of $501.40 per share, with individual trade prices ranging from $501.00 to $502.05. Following this sale, he directly holds 68,418 shares of Chemed stock, and no Rule 10b5-1 trading plan is indicated.
CHEMED CORP (CHE) executive vice president Spencer S. Lee reported selling 1,000 shares of CHEMED CORP capital stock on August 21, 2026 in an open-market or private transaction at a price of $541.04 per share. After this sale, Lee directly holds 13,912 shares of CHEMED CORP capital stock.
CHEMED CORP (CHE) reported that president and CEO Kevin J. McNamara sold 2,000 shares of Chemed capital stock on 2026-08-21 in an open market or private transaction. The weighted average sale price was reported as $541.16 per share, with individual trade prices ranging from $539.62 to $542.53. After this transaction, McNamara directly held 70,418 shares of Chemed capital stock. The company notes that full trade-by-trade pricing details are available upon request.
Chemed Corporation (CHE) received a notice under Rule 144 that officer Kevin J. McNamara plans to sell 2,000 shares of common stock through Merrill Lynch on or about 08/21/2026. The shares relate to a stock award and stock exercise dated 02/14/2025. Chemed reports 13,069,961 shares outstanding, a baseline figure, not the amount being sold.
Chemed Corp is reported to have a significant institutional shareholder. As of June 30, 2026, AQR Capital Management, LLC and its parent AQR Capital Management Holdings, LLC together beneficially owned 972,474 shares of Chemed capital stock, representing 7.25% of the class. They report shared voting power over 962,897 shares and shared dispositive power over 972,474 shares, with no sole voting or dispositive power. AQR Capital Management, LLC is a wholly owned subsidiary of AQR Capital Management Holdings, LLC, and both entities have jointly reported this ownership.
Chemed Corp executive Brian C. Judkins, VP and Chief Legal Officer, exercised stock options covering 6,786 shares of capital stock at an exercise price of $445.35 per share. The options, which vest in three equal annual installments beginning 10/28/2022, now leave him with 31,281 option-based shares outstanding. To fund the option purchase and related tax obligation, 5,878 shares of capital stock were delivered or withheld at $548.96 per share.
Chemed Corp executive Joel L. Wherley, CEO of Vitas Healthcare, exercised stock options for 2599.0000 shares of capital stock at $445.3500 per share on 2026-08-05. The options, vesting in three equal annual installments commencing 10/28/2022, were fully exercised, leaving him with 30220.0000 direct shares. In a related transaction, 2270.0000 shares of capital stock at $542.6200 per share were withheld to cover the purchase price and tax obligation on the option exercise.
Chemed Corp president and CEO Kevin J. McNamara reported an option exercise and related share dispositions. He exercised stock options for 2,001 shares at $445.35 and sold 2,000 shares of capital stock at a weighted average $539.51. An additional 19,802 shares were withheld to pay the option purchase price and related tax obligations. After the derivative transaction, he directly held 264,158 stock options.
Chemed Corporation has a holder preparing to sell 2,000 shares of common stock through Merrill Lynch, with the shares listed on the NYSE. The planned sale has an aggregate market value of $1,064,500, compared against 13,069,961 shares outstanding.
The seller previously acquired Chemed stock through stock awards and related stock exercises, including 1,656 shares tied to a transaction dated May 2, 2023 and 344 shares tied to a transaction dated August 3, 2023.